SFM
TEVA icon

Soros Fund Management’s Teva Pharmaceuticals TEVA Stock Holding History

Soros Fund Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-1,425,000
Closed -$57.1M – 361
2013
Q4 		$57.1M Buy
+1,425,000
New +$56.1M 0.49% 57

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Soros Fund Management's TEVA Position: Q4 2018 in Review

Soros Fund Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2018, closing a stake of 160,000 shares — an estimated $3.28M sold.

Soros Fund Management first reported a position in TEVA in Q3 2013 and held it in 9 quarters. The position peaked at $545M in Q1 2014. 552 funds tracked by Wall St. Rank hold TEVA as of Q4 2018.

  • Soros Fund Management reported no remaining Teva Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Soros Fund Management sold 160,000 Teva Pharmaceuticals shares in Q4 2018, an estimated $3.28M.
  • Soros Fund Management first reported a position in Teva Pharmaceuticals in Q3 2013 and held it in 9 quarters.
  • Soros Fund Management's Teva Pharmaceuticals position peaked at $545M in Q1 2014.
  • 552 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2018.

Based on Soros Fund Management's 13F filing for Q4 2018, filed 14 Feb 2019.